News FDA warns of genital gangrene risk with diabetes drug class The US regulator released an official risk warning of a rare genital infection identified in 12 patients, including one fatality, after using SGLT2 class drugs for type 2 diabetes.
Views & Analysis SGLT2 inhibitors: an emerging option for cardiologists? With studies showing potential for SGLT2 inhibitors in heart failure, a study of HCP online conversations reveals cardiologists are still cautious.
UK & Europe AZ’s diabetes combination Qtern approved in Europe The European Commission has granted marketing approval to a new combination pill from AstraZeneca to treat type 2 diabetes.
News Tenax trounced by phase 3 heart failure readout Shares in Tenax 85% of their value after its drug for patients with pulmonary hypertension caused by a form of heart failure flunked a phase 3 trial.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
